The annual fee that you pay to the fund company for managing your investment. The lower the expense ratio, the better. This is not an investment recommendation.

Dividends

1.22%Dividend Yield

Dec 2025

$0.47

Dec 2024

$0.47

10Y Growth

N/A

5Y Growth

N/A

3Y Growth

N/A

1Y Growth

0.77%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow HRTS. It's not an investment recommendation.

Schwab U.S. Large-Cap Growth

SCHG

Amazon

AMZN

Schwab US Dividend Equity

SCHD

iShares 0-3 Month Treasury Bond

SGOV

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Lilly(Eli) &

LLY

Mkt Cap1.02T

Eli Lilly produces drugs for diabetes and related metabolic conditions, overlapping with obesity management.

Astrazeneca

AZN

Mkt Cap243.34B

AstraZeneca offers various treatments for cardiovascular and metabolic diseases, aligning closely with cardiometabolic healthcare.

Sanofi

SNY

Mkt Cap95.65B

Sanofi operates extensively in the diabetes and cardiovascular sectors, competing in similar markets as HRTS.

Merck

MRK

Mkt Cap356.01B

Merck provides medications for diabetes and heart diseases, which are key areas in cardiometabolic health.

AMGEN

AMGN

Mkt Cap217.9B

Amgen focuses on cardiovascular disease treatments, directly impacting the cardiometabolic therapy market.

Novartis

NVS

Mkt Cap268B

Novartis offers drugs for chronic heart conditions and metabolic disorders, competing in the cardiometabolic space.

Pfizer

PFE

Mkt Cap158.45B

Pfizer has a range of treatments for cardiovascular diseases, which places them as a competitor in the cardiometabolic field.

GSK

Mkt Cap94.23B

GlaxoSmithKline engages in the development of therapies for diabetes and heart diseases, relevant to cardiometabolic health.

Bristol-Myers Squibb

BMY

Mkt Cap124.91B

Bristol Myers Squibb produces medications for cardiovascular diseases, making them a competitor in the cardiometabolic sector.

Holdings

Regions

Sectors

About

The Tema Heart & Health ETF (HRTS) is designed to strategically invest in companies poised to benefit from cutting-edge developments within the biotechnology and broader healthcare industries. Its investment mandate specifically targets firms focused on advancing treatments and therapies for cardiovascular health, metabolic disorders, and weight management.

CEO

Country

United States

ISIN

US87975E8839

Listings

0 Comments

Share your thoughts

FAQs

What is Tema Heart & Health stock price today?▼

The current price of HRTS is $38.87 USD — it has increased by +1.76% in the past 24 hours. Watch Tema Heart & Health stock price performance more closely on the chart.

What is Tema Heart & Health stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Tema Heart & Health stocks are traded under the ticker HRTS.

Is Tema Heart & Health stock price growing?▼

HRTS stock has risen by +3.78% compared to the previous week, the month change is a +8.12% rise, over the last year Tema Heart & Health has showed a +19.33% increase.

Does Tema Heart & Health pay dividends?▼

Yes, HRTS dividends are paid annual. The last dividend per share was 0.47 . As of today, Dividend Yield (FWD)% is 1.22%.

In which sector is Tema Heart & Health located?▼

Tema Heart & Health operates in the Finance & Payments sector.

When did Tema Heart & Health complete a stock split?▼

Tema Heart & Health has not had any recent stock splits.

Where is Tema Heart & Health headquartered?▼

Tema Heart & Health is headquartered in New York, United States.